Beckman and Affymetrix Coulter forge alliance to provide optimized genomic research solutions Affymetrix, Inc. and Beckman Coulter, Inc article . Today announced that they have entered into an contract to provide researchers co-developed items from the marketplace leaders in microarrays and automated liquid handlers. The collaboration will provide scientists with optimized, robust solutions for genomic study, fortified by end-to-end support. This platform provides researchers with standardized systems that include all components essential to operate Affymetrix genotyping and gene expression assays..
Registration technique for Hematide. Subject to opinions from the FDA, the program is to pursue a New Drug Application for treatment of anemia in dialysis patients, while continuing to evaluate the non-dialysis indication. The timeline for feasible submission of the NDA will end up being aimed for initial half of 2011, but will be finalized after the FDA meeting.. Affymax, Takeda announce preliminary technique for Hematide to take care of anemia in chronic renal failure patients Affymax, Inc. Related StoriesCirculating protein predicts risk of chronic kidney diseaseAmgen announces submission of supplemental New Drug Application to FDA for Kyprolis Only 1 1 in 4 sufferers with ESRD in Georgia known for kidney transplant evaluationAffymax and Takeda are continuing to carry out further evaluation of the PEARL and EMERALD studies which evaluated the efficacy and safety of Hematide in chronic renal failing sufferers with anemia.